Philipp von Gallwitz
Prior to co-founding patient engagement expert admedicum® Business for Patients in 2016, Philipp gathered almost 20 years of management experience in R&D-based pharma. He is also a registered Attorney at Law in Cologne, Germany. He is a father to a severely disabled daughter due to an unknown disorder very similar to ultra-rare CDKL5 Deficiency Disorder (CDD). He is an internationally active patient representative of CDKL5 e.V. Germany.
Between 2011-2014 Philipp was CEO of Grunenthal US Inc. in NJ, USA, then Head of Portfolio Development R&D at Grunenthal Headquarters in Germany until the foundation of his own venture. Philipp led strategic search programs for future therapeutic fields, among them numerous rare diseases, neuro-muscular and inflammation disorders. During this time Philipp started several initiatives for engaging patients in R&D. His belief that patient-oriented business thinking is one of the keys for future sustainable healthcare triggered his decision to start his own venture in 2016.
In 2017 and 2018 he also helped the US group Locust Walk, global transaction advisors for biotech, pharma and medtech, to establish their European footprint.
Philipp has lived and worked in Spain, Ecuador, Mexico, the US and Germany and has year-long intensive experience in Japan. Prior to moving to the US in 2011, he filled positions in product management, corporate strategy, business development and corporate leadership positions in licensing and alliance management. His special interest has always been with innovative R&D, building and fostering partnerships and deal making.
In 2016 Philipp co-founded admedicum® Business for Patients, experts in patient engagement and patient access. admedicum® helps biotech, pharma and medtech companies understanding patient-needs and establishing sustainable value-adding collaboration between patients and industry across the life-cycle of the product from early R&D through to commercialization. Philipp provides more information in this short video.